Nuvation reroutes its glioma plan
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Novartis trips over the Hippo
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
Merck gets two Welireg wins
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
Triple meeting 2025 – Halda’s proximity play in prostate
Early data with the RIPTAC HLD-0915 look competitive.
Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
